Description:
"Epilepsy is a major public health problem: it is a chronic noncommunicable disease of the
brain that affects more than 50 million people worldwide. Epilepsy accounts for 0.5% of
the global burden of disease and is associated with stigma, physical and psychiatric
comorbidity, and high economic costs. Nearly 80% of people living with epilepsy reside in
low- and middle-income countries, and 75% do not receive the treatment they need.
Over half of the people living with epilepsy worldwide are estimated to live in Asia. In
comparison with Africa, Asia has more untreated patients, with greater treatment costs
and possibly higher premature mortality. According to the WHO Atlas: country resources
for neurological disorders (second edition), the median number of neurologists is extremely
low in South-East Asia (0.1 per 100 000 population) and the Western Pacific (1.2) – far
fewer than the ratio in Europe (6.6).
In Myanmar, it is estimated that around 500 000 people live with epilepsy, a prevalence of 1.1
per 1000 population. An estimated 95% of people living with epilepsy do not receive the care
required. The main reasons for this include the limited number of health care providers trained
to provide care and support to people living with epilepsy, the limited access to anti-seizure
medications, and a lack of awareness and health education about epilepsy.
For more than 20 years, the WHO has led the global movement against epilepsy. Within
the framework of the Global Campaign Against Epilepsy, WHO aims to bring epilepsy “out
of the shadows”, encouraging countries to prioritize epilepsy in public health planning, as well
as raise awareness of the disease among health care providers and the general public.
The WHO Programme on reducing the epilepsy treatment
gap seeks to achieve these goals in pilot locations in
Myanmar, Ghana, Mozambique and Viet Nam, which can
be used as a model for scale up in other countries. The
Programme offers an innovative community-based model
focused on expanding the skills of nonspecialist health
care providers to diagnose, treat and follow up people
living with epilepsy.
Epilepsy is included as a priority condition in the WHO
mental health Gap Action Programme (mhGAP). It’s
evidence-based guidelines facilitate delivery of interventions by nonspecialist health care providers and is used in
the WHO Programme on reducing the epilepsy treatment
gap to strengthen care provided for people living with
epilepsy and their families. The Programme also includes
strengthening of health systems to increase sustainable
access to anti-seizure medications, reinforcing referral
systems, ensuring better monitoring of epilepsy in health
information systems, and raising awareness to support
people living with epilepsy and their families.
The Myanmar Epilepsy Initiative was launched in 2013
in a phased approach. In 2013, the project was initiated
in the two townships of Hlegu and Hmawbi and then
subsequently scaled up to Lewe, Kawhmu and Thalyinin
2014; Nyaundon, Thaton and Kyaikhto in 2015; Sagaing
and Taunggyi in 2016, and Nyaunglebin and Pantanaw in
2017. The project gradually expanded to 12 townships,
from seven states/regions, covering 2.9 million people.
In 2013 and 2014, situation analyses and baseline
surveys were carried out in the first five project townships
to better understand the existing needs and resources.
The prevalence of epilepsy ranged from 0.83 to 1.9
per 1000 population in the surveyed townships, with
an average prevalence of 1.4 per 1000 population that
was used to estimate the number of people living with
epilepsy in other townships for planning purposes..."
Source/publisher:
World Health Organisation (WHO)
Date of Publication:
2017-01-01
Date of entry:
2019-06-13
Grouping:
- Individual Documents
Category:
Countries:
Myanmar
Language:
English
Local URL:
Format:
pdf
Size:
2.38 MB
Resource Type:
text
Text quality:
- Good